Diversion of methadone and buprenorphine from opioid substitution treatment: A staff perspective

Journal of Psychoactive Drugs

Volumn 46, Issue 5, 2014, Pages 427-435

  Johnson, Björn ^a   Richert, Torkel ^a  

^a MALMÖ UNIVERSITY   (Sweden)

Author keywords

Buprenorphine; Diversion; Illicit use; Methadone; Opioid substitution treatment; Staff perspective

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; METHADONE;

ARTICLE; COMPREHENSION; DRUG APPROVAL; DRUG MARKETING; DRUG TOLERANCE; DRUG USE; HEALTH CARE ACCESS; HELP SEEKING BEHAVIOR; HUMAN; INFORMATION DISSEMINATION; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; MORTALITY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PATIENT COMPLIANCE; SEMI STRUCTURED INTERVIEW; SOCIAL INTERACTION; OPIOID-RELATED DISORDERS;

BUPRENORPHINE; HUMANS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS;

EID: 84920716595     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2014.960109     Document Type: Article

References (45)

1. Amato, L.; Minozzi, S.; Davoli, M. & Vecchi, S. 2011. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database of Systematic Reviews doi:10.1002/14651858.CD004147.pub4.
2. Baldwin, H. & Duffy, P. 2013. Drug treatment practitioners’ perceptions of methadone diversion and their responses to it. Drugs: Education, Prevention and Policy 20 (1): 22-32.
3. Bourdieu, P. 1982. Outline of a Theory of Practise. Cambridge: Cambridge University Press.
4. Bourgois, P. 2000. Disciplining addictions: The bio-politics of methadone and heroin in the United States. Culture, Medicine and Psychiatry 24 (2): 165-195.
5. Caplehorn, J.R.M.; Irwig, L. & Saunders, J.B. 1996. Physicians’ attitudes and retention of patients in their methadone maintenance programs. Substance Use & Misuse 31 (6): 663-677.
6. Caplehorn, J.R.M.; Lumley, T.S. & Irwig, L. 1998. Staff attitudes and retention of patients in methadone maintenance programs. Drug and Alcohol Dependence 52 (1): 57-61.
7. Conrad, P. & Schneider, W. 1992. Deviance and Medicalization. Philadelphia, PA: Temple University Press.
8. Dale-Perera, A.; Goulão, J. & Stöver, H. 2012. Quality of care provided to patients receiving opioid maintenance treatment in Europe. Heroin Addiction and Related Clinical Problems 14 (4): 23-38.
9. Ekendahl, M. 2011. The limits of legitimacy: Service providers’ views on maintenance treatment in Sweden. Addiction Research and Theory 19 (5): 427-37.
10. Fraser, S. & Valenine, K. 2008. Substance & Substitution: Methadone Subjects in Liberal Societies. New York: Palgrave Macmillan.
11. Fountain, J.; Strang, J.; Gossop, M.; Farrell, M. & Grifiths, P. 2000. Diversion of prescribed drugs by drug users in treatment: Analysis of the UK market and new data from London. Addiction 95 (3): 393-406.
12. Fugelstad, A. 2012. Utvecklingen av Akuta Narkotikarelaterade Dödsfall 1994-2011. Stockholm: Karolinska institutet.
13. Fugelstad, A.; Johansson, L.A. & Thiblin, I. 2010. Allt fler dör av metadon: “äckage” från dagens mer liberala behandlingsprogram kan vara en orsak. Läkartidningen 107 (18): 1225-1228.
14. Fugelstad, A.; Stenbacka, M.; Leifman, A.; Nylander, M. & Thiblin, I. 2007. Methadone maintenance treatment: The balance between lifesaving treatment and fatal poisonings. Addiction 102 (3): 406-412.
15. Gerra, G.; Saenz, A.; Maremmani, I.; Ciccocioppo, R.; Zaimovic, R.; Gerra, M.L.; Amore, M.; Manfredini, M.; Donnini, C. & Somaini, L. 2011. Supervised daily consumption, contingent take-home incentive and non-contingent take-home in methadone maintenance. Progress in Neuro-Psychopharmacology & Biological Psychiatry 35 (2): 483-489.
16. Gwin Mitchell, S.; Kelly, S.M.; Brown, B.S.; Schacht Reisinger, H.; Peterson, J.A.; Ruhf, A.; Agar, M.H.; O’Grady, K.E. & Schwartz, R.P. 2009. Uses of diverted methadone and buprenorphine by opioidaddicted individuals in Baltimore, Maryland. The American Journal of Addictions 18 (5): 346-55.
17. Håkansson, A.; Medvedeo, A.; Andersson, M. & Berglund, M. 2007. Buprenorphine misuse among heroin and amphetamine users in Malmö, Sweden: Purpose of misuse and route of administration. European Addiction Research 13 (4): 207-215.
18. Heinemann, A.; Iwersen-Bergmann, S.; Stein, S.; Schmoldt, A. & Püschel, K. 2000. Methadone-related fatalities in Hamburg 1990-1999: Implications for quality standards in maintenance treatment? Forensic Science International 113 (1-3): 449-455.
19. Johnson, B. 2007. After the storm: Developments in maintenance treatment policy and practice in Sweden 1987-2006. In: J. Edman & K. Stenius (Eds.) On the Margins. Helsingfors: NAD.
20. Johnson, B. & Hagström, B. 2005. The translation perspective as an alternative to the policy diffusion paradigm: The case of the Swedish methadone maintenance treatment. Journal of Social Policy 34 (3): 365-388.
21. Johnson, B. & Svensson, B. 2006. Metadonkonflikten. In: V. Denvall & B. Vinnerljung (Eds.) Nytta och Fördärv. Stockholm: Natur och Kultur.
22. Larance, B.; Degenhadt, L.; O’Brien, S.; Lintzeris, N.; Winsock, A.; Mattick, R.P.; Bell, J. & Ali, R. 2011. Prescribers’ perceptions of the diversion and injection of medication by opioid substitution treatment patients. Drug and Alcohol Review 30 (6): 613-620.
23. Lipsky, M. 1980 Street-level bureaucracy. New York: Russell Sage Foundation.
24. Madden, M.E. & Shapiro, S.L. 2011. The methadone epidemic: Methadone-related deaths on the rise in Vermont. American Journal of Forensic Medicine & Pathology 32 (2): 131-135.
25. Mattick, R.P.; Breen, C.; Kimber, J. & Davoli, M. 2009. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews doi: 10.1002/14651858.CD002209.pub2
26. Mattick, R.P.; Kimber, J.; Breen, C. & Davoli, M. 2008. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database of Systematic Reviews doi:10.1002/14651858.CD002207.pub3
27. Morgan, O.; Griffiths, C. & Hickman, M. 2006. Association between availability of heroin and methadone and fatal poisoning in England andWales 1993-2004. International Journal of Epidemiology 35(6): 1579-1585.
28. Otiashvili, D.; Zabransky, T.; Kirtadze, I.; Piralishvili, G.; Chavchanideze, M. & Miovsky, M. 2010. Why do the clients of Georgian needle exchange programmes inject buprenorphine? European Addiction Research 16 (1): 1-8.
29. Petersson, F. 2013. Controlling Addiction. Malmö: Égalité.
30. Rees Davis, W. & Johnson, B.D. 2007. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug and Alcohol Dependence 92 (1-3): 267-276.
31. Richert, T. & Johnson, B. 2013. Illicit use of methadone and buprenorphine among adolescents and young adults in Sweden. Harm Reduction Journal 10: 27.
32. Ritter, A. & Di Natale, R. 2005. The relationship between take-away methadone policies and methadone diversion. Drug and Alcohol Review 24 (4): 347-352.
33. Roche, A.; McCabe, S. & Smyth, B.R. 2008. Illicit methadone use and abuse in young people accessing treatment for opiate dependence. European Addiction Research 14 (4): 219-25.
34. Rosenbaum, M. 1995. The demedicalization of methadone maintenance. Journal of Psychoactive Drugs 27 (2): 145-149.
35. Schmidt, C.S.; Schulte, B.; Wickert, C.; Thane, K.; Kuhn, S.; Verthein, U. & Reimer, J. 2013. Non-prescribed use of substitution medication among German drug users: Prevalence, motives and availability. International Journal of Drug Policy 24 (6): e111-4. doi:10.1016/j.drugpo.2013.04.006.
36. Seymour, A.; Black, M.; Jay, J.; Cooper, G.; Weir, C. & Oliver, J. 2003 The role of methadone in drug-related deaths in the west of Scotland. Addiction 98 (7): 995-1002.
37. Sjöberg, C. 2013. Dags för debatt om missbruksvården. Läkartidningen 109 (49-50): 2296-7.
38. Solomon, S.S.; Desai, M.; Srikrishana, A.; Thamburaj, E.; Vasudevan, C.K.; Kumar, M.S.; Solomon, S.; Celentano, D.D. & Mehta, S.H. 2010. The profile of injection drug users in Chennai, India: Identification of risk behaviours and implications for interventions. Substance Use & Misuse 45 (3): 354-367.
39. Spunt, B.; Hunt, D.E.; Lipton, D.S. & Goldsmith, D.S. 1986. Methadone diversion: A new look. The Journal of Drug Issues 16 (4): 569-583.
40. Stoller, K.B. & Bigelow, G.E. 1999. Regulatory, cost, and policy issues. In: E.C. Strain & M.L. Stitzer (Eds.) Methadone Treatment for Opioid Dependence. Baltimore, MD: Johns Hopkins University Press.
41. Strang, J.; Hall, W.; Hickman, M. & Bird, S.M. 2010. Impact of supervision of methadone consumption on deaths related to methadone overdose (1993-2008). BMJ 341: c5475.
42. Svensson, B. & Andersson, M. 2012. Involuntary discharge from medication-assisted treatment for people with heroin addiction: Patients’ experiences and interpretations. Nordic Studies on Alcohol and Drugs 29 (2): 173-193.
43. U.S. Department of Justice. 2007 Methadone Diversion, Abuse, and Misuse. Johnstown, PA: National Drug Intelligence Center.
44. Winsock, A.R. & Lea, T. 2010. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia. Substance Use & Misuse 45 (1-2): 240-252.
45. Winsock, A.R.; Lea, T. & Jackson, A.P. 2009. Methods and motivations for buprenorphine diversion from public opioid substitution treatment clinics. Journal of Addictive Diseases 28 (1): 57-63.